Clinical Trial

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Study acronym: ComPACT
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase Ib followed by phase II clinical trial evaluating the safety and efficacy of combination of ADG106 with pembrolizumab in patients with metastatic cancers. The Phase Ib dose finding part will include all solid tumor subtypes with treatment refractory disease, while phase II will focus on only patients with TNBC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-05; most recent amendment 2025-07-22.
Status change: Not Yet Recruiting → Recruiting 2023-07-17
Trial Details
NCT Number NCT05491083
Lead Sponsor National University Hospital, Singapore
Collaborators: Adagene Inc, Merck Sharp & Dohme LLC
Conditions Advanced Solid Tumor, Triple Negative Breast Cancer
Enrollment 51 participants
Start Date 2023-06-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-25